Cefepime/Enmetazobactam (Exblifep) for Complicated Urinary Tract Infections

The FDA has approved Exblifep (Allecra), a fixed-dose combination of the cephalosporin cefepime and the beta-lactamase inhibitor enmetazobactam, for IV treatment of adults with complicated urinary tract infections (cUTIs), including pyelonephritis, caused by designated susceptible microorganisms. Exblifep is the first product that contains enmetazobactam to be approved in the US.